TGF-β inhibition of CTL re-stimulation requires accessory cells and induces peroxisome-proliferator-activated receptor-gamma (PPAR-γ)

American Journal of Transplantation

Volumn 6, Issue 8, 2006, Pages 1809-1819

  VanBuskirk, A M ^a,b   Lesinski, G B ^a   Nye, K J ^a   Carson, W E ^a,b   Yee, L D ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

CTL; IFN ; Post transplant lymphoproliferative disorder (PTLD); PPAR ; TGF

Indexed keywords

CD14 ANTIGEN; CIGLITAZONE; GAMMA INTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA;

ACCESSORY CELL; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL POPULATION; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOPROLIFERATIVE DISEASE; MEMORY CELL; MEMORY T LYMPHOCYTE; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; UPREGULATION;

ANTIGEN-PRESENTING CELLS; CELL LINE; GENE EXPRESSION REGULATION; HERPESVIRUS 4, HUMAN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; INTERFERON-GAMMA; PPAR GAMMA; T-LYMPHOCYTES, CYTOTOXIC; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 33745812858     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01387.x     Document Type: Article

References (74)

1. Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr Virus-induced posttransplant lymphoproliferative disorders. Transplantation 1999; 68: 1517-1525.
2. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
3. Hague T, Wilkie GM, Taylor C et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-442.
4. Haque T, Taylor C, Wilkie GM et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399-1402.
5. Porcu P, Eisenbeis CF, Pelletier RP et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood 2002; 100: 2341-2348.
6. Shin GT, Khanna A, Ding R et al. In vivo expression of transforming growth factor-beta1 in humans: Stimulation by cyclosporine. Transplantation 1998; 65: 313-318.
7. Khanna A, Cairns V, Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999; 67: 614-619.
8. Xu J, Menezes J, Prasad U, Ahmad A. Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer 1999; 84: 396-399.
9. Dierksheide JE, Baiocchi RA, Ferketich AK et al. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood 2005; 105: 1558-1565.
10. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16: 137-161.
11. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999; 10: 303-360.
12. Kelly DL, Rizzino A. Growth regulatory factors and carcinogenesis: The roles played by transforming growth factor beta, its receptors and signaling pathways. Anticancer Res 1999; 19: 4791-4807.
13. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002; 99: 3179-3187.
14. Ranges GE, Figari IS, Espevik T, Palladino MAJ. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 1987; 166: 991-998.
15. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992; 52: 1386-1392.
16. Kezuka T, Streilein JW. Analysis of in vivo regulatory properties of T cells activated in vitro by TGFbeta2-treated antigen presenting cells. Invest Ophthalmol Vis Sci 2000; 41: 1410-1421.
17. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000; 164: 1269-1276.
18. King C, Davies J, Mueller R et al. TGF-b1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998; 8: 601-613.
19. Strobl H, Knapp W. TGF-beta1 regulation of dendritic cells. Microbes Infect 1999; 1: 1283-1290.
20. Rosen ED, Sarraf P, Troy AE et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611-617.
21. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
22. Spiegelman BM, Hu E, Kim JB, Brun R. PPAR gamma and the control of adipogenesis. Biochimie 1997; 79: 111-112.
23. Ricote M, Welch JS, Glass CK. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm Res 2000; 54: 275-280.
24. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
25. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
26. Fan W, Yanase T, Morinaga H et al. Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB. Endocrinology 2005; 146: 85-92.
27. Kintscher U, Wakino S, Bruemmer D et al. TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes. Biochem Biophys Res Commun 2002; 297: 794-799.
28. Carrodeguas L, Orosz CG, Waldman WJ, Sedmak DD, Adams PW, VanBuskirk AM. Trans vivo analysis of human delayed-type hypersensitivity reactivity. Hum Immunol 1999; 60: 640-652.
29. VanBuskirk A, Burlingham W, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145-155.
30. Burlingham WJJ-GE, VanBuskirk AM, Pelletier RP, Orosz CG: Delayed Type Hypersensitivity Responses. In: Michael T, Lotze AWT, eds. Measuring Immunity; Basic Biology and Clinical Assessment. Amsterdam, Boston, Heidelberg, London, New York: Elsevier Academic Press, 2005: 407-418.
31. Nociari MM, Shalev A, Benias P, Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods 1998; 213: 157-167.
32. Wilson AD, Hopkins JC, Morgan AJ. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors. Clin Exp Immunol 2001; 126: 101-110.
33. Yee LD, Young DC, Rosol TJ, Vanbuskirk AM, Clinton SK. Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. J Nutr 2005; 135: 983-988.
34. Lesinski GB, Kondadasula SV, Crespin T et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 2004; 96: 1331-1342.
35. Burlingham WJ, Jankowska-Gan E, VanBuskirk A, Orosz CG, Lee J, Kusaka S. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: Evidence from trans-vivo DTH and alloantibody analysis. Hum Immunol 2000; 61: 1395-1402.
36. Baiocchi RA, Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in □scid/scid□ mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 5577-5581.
37. Buchsbaum RJ, Fabry JA, Lieberman J. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in seid mice. Immunol Lett 1996; 52: 145-152.
38. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J Exp Med 1996; 183: 1215-1228.
39. Lacerda JF, O'Reilly RJ. Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice. Ann Oncol 1997; 8(Suppl 2): 137-140.
40. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism [see comments]. Nature 1999; 397: 530-534.
41. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749-795.
42. Cantin E, Tanamachi B, Openshaw H. Role for gamma interferon in control of herpes simplex virus type 1 reactivation. J Virol 1999; 73: 3418-3423.
43. Lotz M, Tsoukas CD, Fong S, Carson DA, Vaughan JH. Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma. Eur J Immunol 1985; 15: 520-525.
44. Shi Y, Lutz CT. Interferon-gamma control of EBV-transformed B cells: A role for CD8+ T cells that poorly kill EBV-infected cells. Viral Immunol 2002; 15: 213-225.
45. Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8T cells. J Immunol 2005; 174: 5215-5223.
46. Kosiewicz MM, Alard P. Tolerogenic antigen-presenting cells: Regulation of the immune response by TGF-beta-treated antigen-presenting cells. Immunol Res 2004; 30: 155-170.
47. Bastos KR, Alvarez JM, Marinho CR, Rizzo LV, Lima MR. Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J Leukoc Biol 2002; 71: 271-278.
48. Takeuchi M, Kosiewicz MM, Alard P, Streilein JW. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation. Eur J Immunol 1997; 27: 1648-1656.
49. Werner F, Jain MK, Feinberg MW et al. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem 2000; 275: 36653-36658.
50. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-609.
51. Ishida Y, Kondo T, Takayasu T, Iwakura Y, Mukaida N. The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol 2004; 172: 1848-1855.
52. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710-713.
53. Soto P, Price-Schiavi SA, Carraway KL. SMAD2 and SMAD7 involvement in the post-translational regulation of Muc4 via the transforming growth factor-{beta} and interferon-{gamma} pathways in rat mammary epithelial cells. J Biol Chem 2003; 278: 20338-20344.
54. Kuga H, Morisaki T, Nakamura K et al. Interferon-gamma suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model. Oncogene 2003; 22: 7838-7847.
55. Monteleone G, Del Vecchio Blanco G, Palmieri G et al. Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. Gastroenterology 2004; 126: 674-682.
56. Monteleone G, Mann J, Monteleone I et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem 2004; 279: 3925-3932.
57. Wen FQ, Liu X, Kobayashi T et al. Interferon-{gamma} inhibits transforming growth factor-{beta} production in human airway epithelial cells by targeting Smads. Am J Respir Cell Mol Biol 2004; 30: 816-822.
58. Mizobuchi T, Yasufuku K, Zheng Y et al. Differential expression of Smad7 transcripts identifies the CD4+CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003; 171: 1140-1147.
59. Gohji K, Nomi M, Hara I, Arakawa S, Kamidono S. Influence of cytokines and growth factors on matrix metalloproteinase-2 production and invasion of human renal cancer. Urol Res 1998; 26: 33-37.
60. Kavsak P, Rasmussen RK, Causing CG et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6: 1365-1375.
61. Fajas L, Debril MB, Auwerx J. PPAR gamma: an essential role in metabolic control. Nutr Metab Cardiovasc Dis 2001; 11: 64-69.
62. Furnsinn C, Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002; 45: 1211-1223.
63. Zhang X, Young HA. PPAR and immune system-what do we know? Int Immunopharmacol 2002; 2: 1029-1044.
64. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005; 51: 85-94.
65. Straus DS, Pascual G, Li M et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 2000; 97: 4844-4849.
66. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999; 66: 733-739.
67. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPAR{gamma} and PPAR{delta} negatively regulate specific subsets of lipopolysaccharide and IFN-{gamma} target genes in macrophages. Proc Natl Acad Sci U S A, 2003.
68. Kintscher U, Goetze S, Wakino S et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2000; 401: 259-270.
69. Waite KJ, Floyd ZE, Arbour-Reily P, Stephens JM. Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. J Biol Chem 2001; 276: 7062-7068.
70. Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: Counter-regulatory activity by IFN-gamma. J Leukoc Biol 2002; 71: 677-685.
71. Floyd ZE, Stephens JM. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem 2002; 277: 4062-4068.
72. Lefebvre AM, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-1057.
73. Saez E, Tontonoz P, Nelson MC et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-1061.
74. Yang K, Fan KH, Lamprecht SA et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ MIh± double mutant mice. Int J Cancer 2005; 116: 495-499.